Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age2+
SponsorMayo Clinic
About this trial
This clinical trial evaluates the effect of radiotherapy doses based on tumor size and tumor-specific characteristics (biologically-adapted) in treating patients with Ewing sarcoma. Radiotherapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Conventional radiotherapy uses minimal imaging support to determine the positioning of radiotherapy. Hypofractionated radiotherapy delivers higher doses of radiotherapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Dose-escalated radiotherapy uses doses that are higher than those used in conventional radiotherapy. Larger tumor sizes and other tumor-specific characteristics have been shown to be related to poorer outcomes. In addition, after dose-escalated radiotherapy, patients with larger tumors have demonstrated improved control of the disease at the primary tumor site. Giving biologically-adapted, dose-escalated radiotherapy may reduce the return of the cancer at the primary tumor site in patients with Ewing sarcoma with large tumors and other unfavorable characteristics. This clinical trial also evaluates the role of biomarkers in patients with Ewing sarcoma. Studying samples of blood and tumor tissue from patients with Ewing sarcoma in the laboratory may help doctors learn more about predicting the amount of disease and the likelihood of the cancer coming back.
Eligibility criteria
Qualifiers
Histological confirmation of Ewing sarcoma, including both skeletal and extra-skeletal primary tumors. Patients with "Ewing-like" sarcoma may be eligible if patients are planned to be treated per Ewing treatment paradigms, as defined in this clinical trial
Patients of age ≥ 2 years are eligible for the study
Lansky or Karnofsky performance status ≥ 70
Ability to provide written informed consent and complete questionnaire(s) by themselves or with assistance
Disqualifiers
Prior chemotherapy or radiotherapy that, in the opinion of the treating medical oncologist or radiation oncologist, is considered to interfere with the current treatment or measurement of outcomes
Receiving any investigational agent which would be considered as a treatment for the primary neoplasm that is considered by the investigator to interfere with the current treatment or measurement of outcomes
Note: Co-enrollment on another clinical trial is allowed per the treating radiation oncologist's discretion
Other active malignancy ≤ 1 year prior to registration that is considered by the investigator to interfere with the current treatment or measurement of outcomes
Trial design
Treatments tested in this trial
- Biospecimen Collection
- Chemotherapy
- Computed Tomography
- Conventional Radiotherapy
- Definitive Surgical Resection
- Dose-escalated Radiation Therapy
- Electronic Health Record Review
- External Beam Radiation Therapy
- Hypofractionated Radiation Therapy
- Magnetic Resonance Imaging
- Positron Emission Tomography
- Questionnaire Administration
- Radiation Therapy
Treatment groups
141 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov